Uncategorized

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference – Hawaii®

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile tests at the 2024 Winter Clinical Dermatology Conference – Hawaii, being held Jan. 12-17 in Honolulu, Hawaii.

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference – Hawaii® Read More »

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Arcutis Biotherapeutics, Inc. announced new individual patient response data showing the vast majority of individuals treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index in 4 weeks.

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program Read More »

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with ZORYVE® topical foam, 0.3%, compared to vehicle i.

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids Read More »

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to BeCell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotech

Cell BioEngines, Inc., founded by visionary Dr. Ajay Vishwakarma aiming to turn cancer into a curable disease announced that the SOSV-backed company will establish its executive headquarters in NYC, a hub for the fast-growing life-science ecosystem across New York state.

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to BeCell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotech Read More »

Scroll to Top